Publication|Videos|July 18, 2024

PurpleLab Accelerates Clinical Trial Lifecycle with Real-World-Data

Author(s)PurpleLab

Jason Gagner (Vice President of Product for Life Science, PurpleLab) talks about clinical trial variables and how PurpleLab is working to maintain patient retention and accelerate site feasibility.

Approximately 80% of clinical trials will face delays at some point in the trial process. Jason Gagner talked with ACT about how PurpleLab uses real-world data to better inform trials and improve their success rates.

Learn More About:

  • Utilizing real-world data (RWD) to assist clinical trials achieve key milestones
  • Employing a criteria specific geographic analysis of patient populations to expedite site feasibility assessments
  • Understanding the impact of diversity, equity, and inclusion (DEI) in clinical trials on meeting trial objectives and timelines
  • Integrating social determinants of health (SDOH) data to minimize patient dropout rates

Related to this article

The Next Evolution of Patient-Centered Trials Starts with Design
Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.